Organon (OGN) Proxy filing summary

Executive summary

• Merger agreement announced between Organon and Sun Pharma, aiming to combine complementary strengths and expand global reach.

• Sun Pharma commits to honoring employee compensation, benefits, and severance for at least one year post-closing.

• Equity awards for employees will be preserved or accelerated, with clear payout terms based on grant date.

• Integration planning and regulatory approvals are ongoing, with open communication promised throughout the transition.

• Forward-looking statements highlight potential risks, including regulatory, operational, and market uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on the proposed merger, with proxy materials to be distributed and a formal vote required.

• Proxy solicitation involves directors, executive officers, and employees as participants.

Board of directors and corporate governance

• Structured governance process implemented during the transition, affecting people-related decisions.

• Information about directors and executive officers is available in the 2026 Annual Meeting Proxy Statement.